

9 May 2025

**Physiomics plc
("Physiomics" or the "Company")**

Contract Award with New UK Client

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new UK client.

The project will involve the application of population Pharmacokinetic (PK) modelling techniques using Phase 1 data to inform the Phase 2 study of a small molecule designed to treat rheumatoid arthritis. The project, valued at £67,500, is expected to complete within the next three months and will be the Company's first rheumatoid arthritis project as well as one of the later development stage projects delivered to date.

The Company has also put in place a Master Service Agreement with the client to define and agree broad commercial terms in relation to envisaged further potential projects in the future.

Dr Peter Sargent, CEO of Physiomics, commented:

"We're delighted to have been selected to support the clinical development of this important programme. This contract award not only represents a new client relationship - the third new client in two months - but also is a reflection of our strategy to broaden our services into new therapeutic areas, being our first project in rheumatoid arthritis. In addition, this project is a great opportunity for us to demonstrate our capabilities in supporting programmes at a more advanced stage of development and is well suited to our expertise. We look forward to contributing meaningful insights that can help accelerate and optimise this molecules progress through the clinic."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO
+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce
+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman
+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journey. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk

journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTGZGGKVRRGKZM